Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Thursday

Crinetics Pharmaceuticals (NASDAQ:CRNX) is expected to announce its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.92) per share and revenue of $0.73 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Crinetics Pharmaceuticals Price Performance

Crinetics Pharmaceuticals stock opened at $34.62 on Tuesday. The company has a market cap of $3.21 billion, a price-to-earnings ratio of -9.28 and a beta of 0.56. Crinetics Pharmaceuticals has a 12 month low of $34.07 and a 12 month high of $62.53. The stock’s 50-day moving average is $42.77 and its 200-day moving average is $50.51.

Analyst Upgrades and Downgrades

CRNX has been the topic of several research reports. Jefferies Financial Group upgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Wednesday, January 22nd. Wolfe Research assumed coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday, February 4th. They issued a “peer perform” rating on the stock. TD Cowen initiated coverage on shares of Crinetics Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating for the company. HC Wainwright reissued a “buy” rating and issued a $81.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Monday, January 13th. Finally, JMP Securities restated a “market outperform” rating and set a $87.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Monday, December 16th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $72.64.

Insider Activity at Crinetics Pharmaceuticals

In related news, insider Dana Pizzuti sold 5,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $39.07, for a total value of $195,350.00. Following the sale, the insider now directly owns 31,748 shares of the company’s stock, valued at $1,240,394.36. This represents a 13.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.00% of the stock is currently owned by company insiders.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.